KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Treasury Shares: 2018-2025

Historic Treasury Shares for Esperion Therapeutics (ESPR) over the last 8 years, with Sep 2025 value amounting to $2.0 million.

  • Esperion Therapeutics' Treasury Shares changed negligibly% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 million, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $2.0 million for FY2024, which is negligibly% changed negligibly from last year.
  • As of Q3 2025, Esperion Therapeutics' Treasury Shares stood at $55.0 million, which was down 0.00% from $55.0 million recorded in Q2 2025.
  • Esperion Therapeutics' Treasury Shares' 5-year high stood at $2.0 million during Q1 2021, with a 5-year trough of $2.0 million in Q1 2021.
  • In the last 3 years, Esperion Therapeutics' Treasury Shares had a median value of $55.0 million in 2025 and averaged $55.0 million.
  • Data for Esperion Therapeutics' Treasury Shares shows a peak YoY spiked of 411.65% (in 2021) over the last 5 years.
  • Esperion Therapeutics' Treasury Shares (Quarterly) stood at $55.0 million in 2021, then remained steady at $55.0 million in 2022, then remained steady at $55.0 million in 2023, then remained steady at $55.0 million in 2024, then remained steady at $55.0 million in 2025.
  • Its last three reported values are $2.0 million in Q3 2025, $2.0 million for Q2 2025, and $2.0 million during Q1 2025.